MAR 0 4 2002 1

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mall in an envelope addressed to the: Assistant

Stephen C. D'Amico Type or print name

Signature Signature

February 1, 2002 Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 09/966,422

FILED: SEPTEMBER 26, 2001

FOR: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR HGPRBMY6, EXPRESSED HIGHLY IN SMALL INTESTINE

Assistant Commissioner for Patents Washington, D.C. 20231

## SUBMISSION OF SUBSTITUTE SEQUENCE LISTING INCLUDING STATEMENT OF VERIFICATION IN RESPONSE TO MISSING PARTS NOTICE

Sir:

In response to the Notice to File Missing Parts of Application, the following has been amended in the Sequence Listing:

A) Line <140> amended to state U.S. Serial Number of Ncn-Provisional Application U.S. 09/966,422.

- B) SEQ ID NO:12 to 19, and 27 to 66 were amended to change the originating species designation from "Artificial" to "Homo sapiens".
- C) Features were added to SEQ ID NO:67 and 68 to correctly define the nucleotide characters "n", "v", and "k" in line <223>.

## In the Sequence Listing

SEQ ID NO:12 to 19, and 27 to 66 were amended in the Sequence Listing to change the originating species designation from "Artificial" to "Homo sapiens". Each of these sequences are polypeptide fragments that derive from the full-length HGPRBMY6 polypeptide (SEQ ID NO:2; Figure 2), and are not artificial peptides. Applicants point out, however, that such polypeptides could be synthesized according to methods described in the Specification, as originally filed.

Support for these amendments to the Sequence Listing may be found by reference to the Specification, as originally filed, specifically paragraph number [166] for SEQ ID NO:12 to 19, paragraph number [183] for SEQ ID NO:27 to SEQ ID NO:41, paragraph number [187] for SEQ ID NO:42 to 50, paragraph number [191] for SEQ ID NO:51 to 53, paragraph number [194] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 53, paragraph number [195] for SEQ ID NO:51 to 55 to 55 to 55 to 55 to 5



NO:54 to 61, and paragraph number [198] for SEQ ID NO:62 to 66, Figure 2, and SEQ ID NO:2 of the Sequence Listing, as originally filed.

SEQ ID NO:67 and 68 were amended in the Sequence Listing to correctly define the nucleotide characters "n", "v", and "k" in the feature line <223>. Moreover, the definition of each nucleotide was amended in the Feature section of SEQ ID NO:67 and 68 from "n=A+C+G+T"; "k=C+G+T"; and "v=C+A+G"; to "n=A, C, G, or T"; "k=C, G, or T"; and "v=C, A, or G"; respectively; to more clearly delineate the intent of the definition. SEQ ID NO:67 and 68 represent oligonucleotides that have randomized regions at certain positions along their length. One skilled in the art of molecular biology would appreciate that only a single nucleotide can reside at any particular nucleotide position for a single polynucleotide molecule.

Support for this amendment to the Sequence Listing may be found by reference to the Specification, as originally filed, specifically paragraph numbers [0289], [0290], and [0291], and the Sequence Listing, as originally submitted. Respectfully, no new matter has been added.

Applicants request the originally submitted paper copy and Computer Readable Form of the Sequence Listing be replaced with the paper copy and Computer Readable Form of the Substitute Sequence Listing submitted herewith. Applicants believe the Substitute Sequence Listing is in compliance with C.F.R. 1.822 and 1.823.

Applicants hereby provide a Computer Readable Form of the Substitute Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Substitute Paper Copy and the Substitute Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Stephen C. D'Amico

Agent for Applicants

Reg. No. 46,652

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

(609) 252-5289 Date: February 1, 2002

- 2 -